Skeletal Effects of the Saturated 3-Thia Fatty Acid Tetradecylthioacetic Acid in Rats by Stunes, Astrid Kamilla et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2011, Article ID 436358, 10 pages
doi:10.1155/2011/436358
Research Article
SkeletalEffectsoftheSaturated 3-ThiaFatty Acid
TetradecylthioaceticAcidinRats
AstridKamillaStunes,1 Irene Westbroek,2 ReidarFossmark,1,3 Rolf Kristian Berge,4,5
JanneElinReseland,6 andUnni Syversen1,7
1Department of Cancer Research and Molecular Medicine, Faculty of Medicine, MTFS, Norwegian University of Science and
Technology, NTNU, Olav Kyrres gate 9, 7489 Trondheim, Norway
2Departments of Orthopedics and Internal Medicine, Erasmus University, 3000 DR, Rotterdam, The Netherlands
3Department of Gastroenterology and Hepatology, St. Olav’s University Hospital, 7006 Trondheim, Norway
4Department of Medicine, University of Bergen, 5020 Bergen, Norway
5Department of Heart Diseases, Haukeland University Hospital, 5021 Bergen, Norway
6Department of Biomaterials, Institute for Clinical Dentistry, University of Oslo, 0317 Oslo, Norway
7Department of Endocrinology, St. Olav’s University Hospital, 7030 Trondheim, Norway
Correspondence should be addressed to Astrid Kamilla Stunes, kamilla.stunes@ntnu.no
Received 28 July 2011; Accepted 6 September 2011
Academic Editor: Beata Lecka-Czernik
Copyright © 2011 Astrid Kamilla Stunes et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
This study explores the skeletal eﬀects of the peroxisome proliferator activated receptor (PPAR)pan agonist tetradecylthioacetic
acid (TTA). Rats, without (Study I) and with ovariectomy (OVX) or sham operation (Study II), were given TTA or vehicle daily
for 4 months. Bone markers in plasma, whole body and femoral bone mineral density and content (BMD and BMC), and body
composition were examined. Histomorphometric and biomechanical analyses (Study I) and biomechanical and μCT analyses
(Study II) of the femur were performed. Normal rats fed TTA had higher femoral BMD and increased total and cortical area
in femur compared to controls. The ovariectomized groups had decreased BMD and impaired microarchitecture parameters
compared to SHAM. However, the TTA OVX group maintained femoral BMC, trabecular thickness in the femoral head, and
cortical volume in the femoral metaphysis as SHAM. TTA might increase BMD and exert a light preventive eﬀect on estrogen-
related bone loss in rats.
1.Introduction
Fatty acids are natural ligands for peroxisome proliferator
activated receptors (PPAR) α, δ,a n dγ. Tetradecylthioacetic
acid (TTA) is a saturated 16 carbon 3-thia synthetic fatty
acid, which also acts as a PPARpan agonist.
Studies have shown multifaceted eﬀects of TTA in
rodents. It induces mitochondrial fatty acid β-oxidation and
c a u s e sr e d u c e dp l a s m al e v e l so ff r e ef a t t ya c i d s( F F A )a n d
triglycerides (TG) in addition to improved insulin response,
anti-inﬂammatory action and lowered oxidative stress [1–
3]. The responses are qualitatively similar to the eﬀects of
n-3 fatty acids, but TTA seems to have a greater biological
potency. A main determinant of the mechanism of action
seems to be the non-β-oxidizability of TTA due to the
sulphur atom in the third position in the carbon chain [4].
TTA is also found to attenuate dyslipidemia in male
patients with type 2 diabetes mellitus [1]. Many of the
eﬀects of TTA in this study point in direction of PPARα
as well as PPARδ activation, with a similar pattern of
lipid lowering eﬀects as observed in patients with impaired
glucose tolerance after treatment with fenoﬁbrate, which is
a selective PPARα agonist [1, 5]. Studies in rodents also
indicate that TTA acts through mechanisms that at least
partly involve PPARα activation [2].
All PPAR subtypes are present in bone cells [6]. We
and others have shown that PPARγ agonists have negative
skeletal eﬀects in rodents, by decreasing bone mass and
deteriorating the architectural structure [7–11]. Increased
fracture incidence has also been observed in patients with
type 2 diabetes treated with glitazones [12–15]. In contrast,
we have demonstrated that administration of fenoﬁbrate2 PPAR Research
has a positive impact on bone, both in normal intact
female rats and ovariectomized rats [7, 8]. The PPARα
agonist bezaﬁbrate and the PPARδ/α agonist linoleic acid
administeredtoratsarealsofoundtoincreasebonemassand
bone formation [16].
Cornish et al. reported that saturated fatty acids inhibit
osteoclastogenesis [17]. In accordance with this, endogenous
n-3 fatty acids have been shown to protect against bone
lossbyattenuatingosteoclastogenesisinovariectomizedmice
[18], and high consumption of ﬁsh, a rich source of omega-3
fatty acids, protected against bone loss during long-duration
spaceﬂight [19].
The PPARpan agonist TTA has been reported to exhibit
multiple positive biological eﬀects; however, the eﬀects of
TTA on bone have so far not been explored. Due to the
diﬀerent eﬀects of PPARγ agonists and PPARα agonists on
bone metabolism, we aimed to examine the skeletal eﬀect
of TTA administration in intact as well as in ovariectomized
female rats. Furthermore, we studied the eﬀect of TTA on
proliferation and diﬀerentiation of bone cells and release
of osteoprotegerin (OPG) and secreted receptor activator of
nuclear factor κB ligand (sRANKL) from preosteoblasts.
2. Methods
TTA was provided by one of the coauthors. Methylcel-
lulose (M7140, Sigma-Aldrich, St. Louis, MO) was used
as solvent/vehicle. Female Fischer-344 and Sprague-Dawley
rats were purchased from Møllegaard’s Breeding Center
(Skensved, Denmark).
2.1. Design of Studies. The Animal Welfare Committee at the
St. Olav’s University Hospital in Trondheim approved the
studies. All rats were housed solely in wire-top cages with
aspen woodchip bedding (B&K Universal Ltd, UK). Room
temperature was 24±1.0◦C with a relative humidity of 40%–
50% and a 12-hour light/dark cycle. The Rat and Mouse Diet
(B&K) and tap water were provided ad libitum.T h ein vivo
studies were performed simultaneously with two previous
published studies, and the controls used are the same as in
[8]f o rS t u d yIa n di n[ 7] for Study II.
Study I. Twenty-four female Fischer rats, eight weeks of age
(203 ± 11g), were randomly assigned to two groups, one
group received methylcellulose (CTR, N = 12) and the other
group methylcellulose with TTA (TTA, N = 12) 35mg/kg
body weight, daily for four months by intragastric gavage.
Study II. Thirty-three female Sprague-Dawley rats, twelve
weeks of age (252 ± 16g), were randomly assigned to
three groups of eleven rats. Ovariectomy is a well-known
and widely used model system for osteoporosis in rodents
[20, 21] and was performed in this study. One group was
sham-operated and given methylcellulose (vehicle) (CTR
SHAM),thetwoothergroupswereovariectomizedandgiven
methylcellulose (CTR OVX) or TTA (90mg/kg body weight)
(TTAOVX),bydailyintragastricgavageforfourmonths.We
applied a higher dose of TTA in Study II, in accordance with
doses previously used in other in vivo studies in rats, without
signs of toxicity [22, 23].
For both studies, the rats were weighed at the start and
monthly throughout the studies. Before all procedures and
sacriﬁce, the animals were anesthetized with 2.0mL/kg body
weight of a combination of ﬂuanison (2.5mg/mL), fentanyl
(0.05mg/mL), and midazolam (1.25mg/mL). Blood was
collected by heart puncture during the ﬁnal anesthesia and
stored at −80◦C until analyses. Liver weights were registered
and femurs from all animals were collected, measured, and
stored at −80◦C for further analyses.
2.2. Dual X-Ray Absorptiometry (DXA) Measurements. Body
weight (g), fat mass (g), lean mass (g), bone mineral content
(BMC) (g), and whole body and femur bone mineral density
(BMD) (g/cm2) were measured by DXA in anesthetized
animals, using a Hologic QDR 4500A and small animal
software.DXAwasperformedinbothStudyIandStudyII,at
the beginning of the studies and after two and four months.
The coeﬃcient of variation (CV) was 2.4% for body weight,
2.2%forfatmass,0.28%forleanmass,0.54%forwholebody
BMC, 3.0% for femur BMC, 0.60% for whole body BMD,
and 0.71% for femur BMD.
2.3.Histomorphometry. Histomorphometryoftheleftfemur
was performed in Study I and evaluated by two persons.
Transverse sections were cut close to the patellar ridge
and also 5.0mm proximal from it. They were grounded
to a thickness of 50um. The sections close to the patellar
ridge were used for calculation of trabecular bone volume
(TBV%), and proximal sections were used for calculation of
corticalthickness.ThesectionsforcalculationofTBV%were
stained with Goldner. For calculation of TBV%, a Merz grid
at a magniﬁcation of 10 × 10 was used. As many squares as
possible, usually about 9–11, were calculated. For calculation
of cortical thickness the central point of the medullary canal
was identiﬁed. By means of an eyepiece the diameters were
calculated in four directions with a 45-degree angle between
each. Medullary, cortical and total cross-sectional areas were
calculated from the mean values. All histomorphometric
measurements were performed blindly.
2.4. Microcomputed Tomography (μCT) Measurements. In
Study II, the proximal femurs, including the femoral
head and the metaphysis of the dissected femurs, were
scanned in a SkyScan 1072 microtomography (SkyScan,
Antwerp, Belgium), with a voxel size of 11.89μm. Scans
were processed, and three-dimensional morphometric anal-
yses of the femurs were done using free software of the
3D-Calc Project (http://www.erasmusmc.nl/47460/386156/
Downloads?lang=en). Femoral head and metaphysis data
sets were analyzed separately. Cortical bone and trabecular
bone were separated using in-house developed software.
For each cross-section in the 3D data set, a virtual mask
of the total bone was created and used to identify the
bone marrow regions in the original image. The marrow
regions were expanded into a mask of the total marrow
cavity using a close operation. Bone inside the total marrowPPAR Research 3
cavity was considered trabecular bone; the remainder was
regarded as cortex. Cortical bone volume (Ct.V, μm3),
cortical thickness (Ct.Th, μm ) ,t r a b e c u l a rb o n ev o l u m e( B V ,
μm3), total bone volume, the region of interest adjacent to
the endocortical boundary including the trabecular bone as
previously described [24]( T V ,μm3), trabecular thickness
(Tb.Th, μm), trabecular bone volume fraction (BV/TV),
connectivity density (CD, 1/mm3)[ 25], and structure model
index (SMI, (0–3)) [26] were determined. SMI indicates
whether the trabeculae are more rodlike (SMI = 3) or more
platelike (SMI = 0), and values between 0 and 3 represent
the volume ratio of rods and plates, analyzed as previously
described [26].
2.5. Biomechanical Testing. In Study I and Study II, the right
femurs were thawed in Ringer’s solution before mechanical
testing of the femoral neck and shaft was performed. The
shafts were fractured 18.7mm from the femoral condyles in
three-point cantilever bending as previously described [27].
In short, the proximal femur was ﬁxed in a clamp, the cam
of the rotating wheel engaged the femoral condyles, and a
fulcrum positioned 18.7mm anteriorly from the condyles
was the third-point of force application. All tests were done
at a loading rate of 0.095 radians/second (5.43◦/second).
The load in the test apparatus, a MTS 858 Mini Bionix
Axial/Torsional Test System (MTS Systems Corporation,
Minn, USA), was measured with an MTS Test Star TM
Sensor Cartridge Force 250N loadcell and registered in MTS
Test Star II software. Ultimate bending moment (M)w a s
calculated as the ultimate load before failure multiplied by
the moment arm by which the load was applied (Newton
Meter, Nm). Energy absorption and stiﬀness were read
directly or calculated from the computer recordings as
previously described [27].
2.6. Plasma Analyses. Osteocalcin in plasma was determined
by a Rat-MID osteocalcin enzyme-linked immunosorbent
assay kit (Nordic Bioscience Diagnostics A/S, Denmark),
accordingtothemanufacturer’sprotocol.Thedetectionlimit
was50ng/mL,andintra-andinterassayvariationswere5.0%
and 5.5%, respectively. The bone resorption marker CTX
in plasma was analyzed by a RatLaps ELISA kit (Nordic
Bioscience Diagnostics A/S) according to the instructions
from the manufacturer. The detection limit was 3.0ng/mL,
and intra- and interassay variations were 5.6% and 10.5%,
respectively.
2.7. Cells and Reagents. MC3T3-E1 (mouse preosteoblasts,
ATCC) and RAW264.7 (mouse preosteoclasts, ATCC) were
maintained in MEMα or Dulbecco’s Modiﬁed Eagle Medium
(DMEM), respectively, (Invitrogen) supplemented with 10%
fetal calf serum (FCS) (EuroClone, Great Britain), 1mM
sodium pyruvate (Gibco BRL, Life Technologies Ltd, Scot-
land), 0.1mg/mL L-glutamine (Gibco), and 10U/mL peni-
cillin/streptomycin (Gibco).
2.8. Proliferation Assay. Proliferation of MC3T3-E1 and
RAW 264.7 cells was studied using 5-bromo-2 -deoxyuridine
(BrdU) incorporation (Roche Molecular Biochemicals,
Mannheim, Germany) as previously described [8].
2.9. Osteoprotegerin (OPG), Secreted Receptor Activator of
Nuclear Factor κB Ligand (sRANKL) and Total Protein
Analyses in Cell Medium. The concentration of OPG and
sRANKL in culture media from preosteoblasts (MC3T3-
E1cells) exposed to TTA was determined by OPG ELISA
(RnD Systems, Minneapolis, Minn, US) and a sRANKL
ELISA (Biomedica, Vienna, Austria) as previously described
[8, 28], respectively. The amount of OPG and sRANKL
was related to the amount of total protein in each sample,
which was measured by a Bradford assay [29] using a dye
concentrate (Bio-Rad, Hercules, Calif, US).
2.10. Bone Marrow Cell Preparation. Bone marrow cells
were obtained from femurs and tibiae from three intact
female Sprague Dawley rats (251 ± 4.5g) by centrifugation
as described by Dobson et al. [30]. Brieﬂy, tibiae and
femurs were removed and all soft tissue was removed. The
proximal ends were cut oﬀ, and the bones brieﬂy centrifuged
(1000g, 10s). The bone marrow pellets from each animal
were pooled and resuspended in culture medium and
passed through a 21-gauge needle to achieve a single-cell
suspension.
2.11. Mineralizing Fibroblast-Colony-Forming Unit Cultures
Assays (mCFU-f). For in vitro studies: Dulbecco’s Modiﬁed
Eagle Medium (DMEM) was supplemented with peni-
cillin/streptomycin (10U/mL), L-glutamine (0.1mg/mL),
sodium pyruvate (1.0mM), (all from Gibco BRL Invitro-
gen, Paisley, UK). MCFU-f cultures assays were performed
essentially as previously described by Scutt et al. [31].
Nucleated bone marrow cells from three female rats were
seeded in DMEM/10% fetal calf serum (FCS) (EuroClone,
Devon, UK) with 10nM dexamethasone (Sigma, Oslo,
Norway), 50μg/mL ascorbic acid (Sigma), and 2.0mM β-
glycerophosphate, in 6 well-plates (1.0 × 106cells/well).
Cells were treated with vehicle (medium) and TTA (1.0
and 10μM). The media were changed after 5 days and
thereafter every second day for 21 days. Cultures were
terminatedbywashingwithphosphate-buﬀeredsaline(PBS)
and ﬁxed by adding cold 100% ethanol. Wells were stained
for alkaline phosphatase (ALP) by addition of 0.5mg/mL
napthol AS-BI phosphate (Sigma) and 1.0mg/mL fast red
B (Sigma) in Tris buﬀer (pH 7.5) for 30 minutes, washed
with distilled water, photographed with a digital camera, and
destained with 100% ethanol over night. Calcium-positive
colonies were stained with 1.0mg/mL alizarin red (Sigma) in
distilled water adjusted to pH 5.5 with NH3 for 30 minutes,
washed with distilled water, photographed, and destained
with 5% perchloric acid for 5 minutes. Collagen-positive
colonies were stained with 1.0mg/mL sirius red (Sigma)
in statured picric acid for 18 hours, washed with distilled
water, and photographed. Picture processing was performed
in Adobe Photoshop software (Adobe, San Jose, Calif, USA)
and quantiﬁcation of colonies was performed using the
ImageQuant Software (Amersham Biosciences, Piscataway,
NJ, USA).4 PPAR Research
Table 1: Body weight, fat and lean mass, femoral and whole body bone mineral content (BMC), and bone mineral density (BMD) in rats at
baseline and after four months of treatment with TTA (Study I).
Months CTR (controls given vehicle) (N = 12) TTA (given TTA) (N = 12)
Body weight (g) 0 215 ±14.0 220 ±7.43
4 235 ±15.9 242 ± 10.8
Fat mass (g) 04 3 .6 ±10.94 8 .8 ±7.98
44 6 .8 ±13.74 8 .2 ±14.5
Lean mass (g) 0 165 ±8.44 160 ±8.44
4 183 ±7.73 186 ± 9.36
Whole body BMC (g) 06 .38 ±0.35 6.39 ±0.35
47 .24 ±0.36 7.31 ±0.37
Femoral BMC (g) 00 .32 ±0.029 0.33 ±0.014
40 .72 ±0.036 0.73 ±0.037
Whole body BMD (g/cm2) 00 .142 ±0.007 0.144 ±0.010
40 .159 ±0.008 0.154 ±0.005
Femoral BMD (g/cm2) 00 .233 + 0.010 0.235 ±0.006
40 .245 ±0.009 0.256 ± 0.011a
Data are presented as mean ± SD, aP<0.05 signiﬁcantly diﬀerent compared to control.
2.12. Statistical Analyses. All measurements were performed
in duplicates or triplets. Data are expressed as mean ± SD
or mean ± SEM, as indicated in ﬁgures and tables. All
data were tested for normality with the D’Agostino-Pearson
omnibus normality test. Normally distributed parameters
were tested with two-tailed unpaired student’s t-test, or
one-way ANOVA with Bonferroni’s post test, while param-
eters without normal distribution were tested with Mann-
Whitney’s two-tailed test or Kruskal-Wallis with Dunn’s post
test. P-values below 0.05 were considered signiﬁcant. In
Study II, all statistical analyses were performed with mutual
comparison between all three groups.
3. Results
3.1. Study I
3.1.1. General Observations and Body Composition. No dif-
ferences in the well-being of the animals were observed, and
none of the animals died or became ill during the study.
There were no diﬀerences in body weight, lean or fat mass
at baseline or at the end of the study (Table 1). The liver
weightsweresigniﬁcantlyhigherinratsgivenTTAcompared
to controls (6.92 ± 0.47g versus 6.32 ± 0.47g, P = 0.005),
as described for PPARα agonists previously [7]. We did
not detect any liver pathology by gross visual inspection;
however, livers were not further examined, as this was not
within the scope of this study. Femur lengths were similar in
the two groups at the end of the study (data not shown).
3.1.2.WholeBodyandFemurBMCandBMD. Therewereno
diﬀerences between the two groups at the beginning of the
study in whole body BMD or whole body and femur BMC
between the two groups (Table 1), while the femoral BMD
was signiﬁcantly higher in rats given TTA for four months,
compared to controls (0.256±0.011g versus 0.245±0.009g,
P = 0.012), (Table 1).
Table 2: Histomorphometric analysis of trabecular bone volume,
total, cortical, and medullary area in distal femur after four months
of treatment with TTA (Study I).
Group
CTR
(controls
given vehicle)
(N = 12)
TTA
(given TTA)
(N = 12)
Trabecular bone volume (%) 22.2 ±5.95 22.1 ±4.70
Total area (mm2)6 .26 ±0.32 6.65 ±0.32a
Cortical area (mm2)3 .99 ±0.29 4.27 ±0.24a
M e d u l l a r ya r e a( m m 2)2 .35 ±0.25 2.37 ±0.15
Dataarepresentedasmean ±SD, aP<0.05 signiﬁcantlydiﬀerent compared
to control.
3.1.3. Histomorphometry and Biomechanical Properties. Rats
fed TTA had signiﬁcantly higher total area (P = 0.015)
and cortical area (P = 0.02) than control rats in the distal
femur(Table 2).Therewerenosigniﬁcantdiﬀerencesintotal
medullary area or trabecular bone volume % in the distal
femur (Table 2). There were no signiﬁcant diﬀerences in
mechanical parameters (ultimate bending moment, stiﬀness,
and energy absorption) of the femoral neck and shaft
(Table 3).
3.1.4. Plasma Measurements. There were no signiﬁcant
diﬀerences in plasma levels of osteocalcin (CTR: 371 ±
96ng/mL versus TTA: 386±83ng/mL) or CTX (CTR: 55.4±
42.8ng/mL versus TTA: 60.7 ± 38.2ng/mL).
3.2. Study II
3.2.1. General Observations and Body Composition. There
were no signiﬁcant diﬀerences between the groups at base-
line, regarding body weight, fat or lean mass. The TTA OVX
group had signiﬁcantly higher liver weights than the two
o t h e rg r o u p s( T T AO V X :9 .31 ± 0.67g versus CTR SHAM:PPAR Research 5
Table 3: Mechanical properties of femoral neck and shaft after four
months of treatment with TTA (Study I).
Group
CTR
(controls
given vehicle)
(N = 12)
TTA
(given TTA)
(N = 12)
Ultimate bending moment (Nm)
Femoral neck 50.8 ±5.17 49.3 ±8.86
Femoral shaft 48.3 ±3.41 45.3 ±4.01
Energy absorption (J ×10
−2)
Femoral neck 119 ±12.0 119 ±16.0
Femoral shaft 112 ±8.00 106 ±9.00
Bending stiﬀness (Nm/◦ ×10
−3)
Femoral neck 0.78 ±0.10 0.75 ±0.11
Femoral shaft 1.05 ±0.18 1.04 ±0.14
7.57 ± 1.04g, P = 0.0004 and versus CTR OVX: 7.67 ±
0.96g, P = 0.0005). No diﬀerences in body composition
between the two ovariectomized groups were observed at
the end of the study (Table 4) ,n o te v e ni nl e a nm a s sw h e n
corrected for the increased liver weights in the TTA OVX
group (data not shown). As expected, the ovariectomized
groups had signiﬁcantly higher body weight, fat and lean
mass than CTR SHAM after both two and four months
(Table 4). The femoral lengths were similar in all groups at
theendofthestudy(CTRSHAM:36.4±0.80mm,CTROVX:
37.2 ±0.89mm and TTA OVX: 37.3 ±0.89mm).
3.2.2. Whole Body and Femur BMC and BMD. BMC or
BMD were equal between the three groups at the beginning
of the study. The TTA OVX group maintained femoral
BMC at SHAM levels, in contrast to the OVX controls
which had signiﬁcantly decreased femoral BMC compared
to CTR SHAM after four months of treatment (Table 4).
No signiﬁcant diﬀerences were observed in total body BMC
between the three groups, while both the CTR OVX and the
TTA OVX groups had signiﬁcantly decreased whole body
and femoral BMD compared to the CTR SHAM group
(Table 2).
3.2.3. Bone Architecture. μCT measurements revealed that
ovariectomized rats fed TTA maintained the trabecular
thickness (Tb.Th) in the femoral head and the cortical vol-
ume (Ct.V) in the femoral metaphysis, at the same levels as
the CTR SHAM group. This is in contrast to ovariectomized
controls, which had signiﬁcantly lower Tb.Th and Ct.V
compared to the CTR SHAM group (Tables 5 and 6).
The other parameters measured by μCT mainly showed
that both ovariectomized groups exhibited impaired bone
architecture compared to CTR SHAM (Tables 5 and 6);
however, there were no signiﬁcant diﬀerences between the
two ovariectomized groups. No signiﬁcant diﬀerences in
connectivity density (CD) were registered between any of the
groups (Tables 5 and 6).
3.2.4. Biomechanical Properties. Both the CTR OVX and the
TTA OVX groups had a signiﬁcant decrease in bending
moment in the femoral neck compared to CTR SHAM
(Table 7). However, unlike the CTR OVX group, the energy
absorption in the femoral neck in the TTA OVX group was
unchanged compared to CTR SHAM (Table 7).
3.2.5. Plasma Measurements. Plasma osteocalcin was signiﬁ-
cantly elevated in both the ovariectomized groups compared
to the CTR SHAM group, while there was no signiﬁcant
diﬀerence between the CTR OVX and TTA OVX groups
(CTR SHAM: 367 ± 1.04ng/mL versus TTA OVX: 459 ±
88.4ng/mL, P = 0.012 and versus CTR OVX: 465 ±
139ng/mL, P = 0.05). There were no diﬀerences in plasma
CTX between the groups (CTR SHAM: 21.7 ± 14.5ng/mL,
CTR OVX: 25.9 ±2.8, TTA OVX: 21.7 ±13.5ng/mL).
3.3. In Vitro Studies
3.3.1. Eﬀect of TTA on Bone Progenitors Proliferation. TTA
inhibited proliferation of RAW 264.7 preosteoclasts in a
dose-dependent manner (20–40%) (Figure 1), but had no
eﬀect on MC3T3-E1 preosteoblast proliferation at the doses
used (1.0nM–10μM) (data not shown).
3.3.2. Eﬀect of TTA on OPG and sRANKL Release from
MC3T3-E1 Preosteoblasts. TTA increased OPG release from
MC3T3-E1 preosteoblasts (1.0 and 10μM, after 12, 24, and
48h) (Figure 2), but had no signiﬁcant eﬀects on sRANKL
release (data not shown).
3.3.3. Diﬀerentiation of Rat Bone Marrow Cells. TTA (1.0
and 10μM) slightly increased the number of ALP-positive
colonies in rat bone marrow cells examined with the mCFU-
f assay, however, this did not reach signiﬁcance (TTA 1.0μM:
120 ± 4.2i n%o fC T R ,T T A1 0 μM: 125 ± 5.6i n%o f
CTR). There was no diﬀerence in the number of calcium
andcollagen-positivecoloniesbetweenratbonemarrowcells
treated with TTA (1.0 and 10μM) and control cells (data not
shown).
4. Discussion
In the present study we provide the ﬁrst evidence for positive
skeletal eﬀects of TTA. In intact female rats, we observed
an increase in femoral BMD compared to controls. Total
and cortical areas of femur were also higher; this was,
however, not reﬂected in superior mechanical properties.
Ovariectomized rats receiving TTA maintained femoral
BMCattheSHAMlevel,whilefemoralBMDaswellaswhole
body BMC and BMD, like CTR OVX, decreased compared
to sham controls. A few microarchitecture parameters were
preserved at SHAM levels in ovariectomized rats fed TTA;
trabecular thickness in the femoral head and cortical volume
in the femoral metaphysic were maintained at SHAM level.
This indicates some protection of TTA against the bone loss
induced by estrogen deﬁciency. Endocortical volume was,
however, signiﬁcantly increased both in the femoral head6 PPAR Research
Table 4: Body weight, fat and lean mass, femoral and whole body bone mineral content (BMC), and bone mineral density (BMD) in mean
values ±SEMinshamcontrols,ovariectomizedcontrols,andovariectomizedratsfedTTA,atbaseline,andaftertwoandfourmonths(Study
II).
Months
SHAM
(sham-operated controls)
(N = 10)
OVX
(ovariectomized controls)
(N = 10)
TTA OVX
(ovariectomized, given TTA)
(N = 10)
Body weight (g)
0 264.1 ±5.6 277.3 ±4.5 273.7 ±11.7
2 280.6 ±6.0 339.2 ±5.7aaa 338.2 ±16.2aaa
4 288.9 ± 6.0 351.8 ±7.1aaa 352.5 ±17.8aaa
Fat mass (g)
02 1 .6 ±2.61 8 .2 ±1.92 0 .1 ±4.2
22 7 .3 ±1.63 8 .8 ±3.0aaa 37.2 ±7.2aaa
42 8 .3 ±2.15 5 .8 ±4.9aaa 51.1 ±8.4aaa
Lean mass (g)
0 233.9 ±3.5 250.7 ± 3.8 248.4 ±14.4
2 244.0 ±5.5 290.1 ±5.6aaa 291.0 ± 20.0aaa
4 251.1 ±4.9 285.7 ±5.9aaa 291.0 ±14.9aaa
Whole body BMC (g)
08 .51 ±0.16 8.41 ± 0.16 8.69 ± 0.52
29 .34 ±0.16 9.81 ± 0.20 10.07 ±0.48
49 .56 ±0.18 10.33 ±0.19 10.32 ±0.48
Femur BMC (g)
00 .418 ±0.005 0.409 ±0.010 0.430 ±0.030
20 .463 ±0.011 0.444 ±0.008 0.464 ±0.025
40 .489 ±0.011 0.456 ±0.007a 0.471 ±0.025
Whole body BMD (g/cm2)
00 .173 ±0.001 0.171 ±0.001 0.175 ±0.005
20 .185 ±0.002 0.179 ±0.002 0.181 ±0.005
40 .184 ± 0.001 0.178 ±0.002aaa 0.178 ±0.004a
Femur BMD (g/cm2)
00 .305 ±0.006 0.292 ±0.004 0.302 ±0.017
20 .312 ±0.004 0.293 ±0.002 0.299 ±0.010
40 .319 ±0.004 0.294 ±0.003aaa 0.295 ± 0.009aa
a,aa,aaaP<0.05, P<0.01, P<0.001 when compared to CTR SHAM group.
Table 5: Mean values ± SD of bone architecture parameters in the femoral head, determined by means of μCT scanning analyses in sham
controls, ovariectomized controls, and ovariectomized rats fed TTA for four months (Study II).
Femoral head CTR SHAM (sham-operated
controls, N = 10)
CTR OVX (ovariectomized
controls, N = 10)
TTA OVX (ovariectomized,
given TTA, N = 10)
Cortical volume (Ct.V) (μm3)3 1 .98 ±2.449 28.26 ±1.491aaa 29.23 ±2.110a
Cortical thickness (Ct.Th) (μm) 449.4 ±18.80 422.3 ±21.21aa 422.9 ±16.89aa
Trabecular bone volume (BV) (μm3)1 0 .94 ±1.365 10.69 ±1.291 11.32 ±1.465
Total volume (TV) (μm3)2 0 .12 ±2.062 23.70 ±2.926aa 25.38 ±2.920aaa
Trabecular thickness (Tb.Th) (μm) 155.2 ±6.893 147.2 ±3.445aa 149.9 ±3.809
Connectivity density (CD) (1/mm3)4 4 .42 ±9.160 46.34 ±7.634 45.50 ±7.698
Structure model index (SMI) (0.0–3.0) 0.6509 ±0.2211 0.9811 ±0.1391aa 1.037 ±0.2294aaa
Trabecular bone volume fraction
(BV/TV) 0.5436 ±0.04273 0.4511 ±0.02421aaa 0.4480 ±0.03645aaa
a,aa,aaaP<0.05, P<0.01, P<0.001 when compared to CTR SHAM group.
and metaphysis compared to SHAM. Our data are in
accordance with previous studies showing a preventive eﬀect
of omega-3 fatty acids on bone loss [17, 19].
The ovariectomized control rats in Study II had both
signiﬁcantly lower gain in femoral BMC and BMD and
reduced biomechanical strength parameters compared to
sham-operated controls. The relatively young age of the rats
may explain why the diﬀerences found between the SHAM
and OVX controls were less pronounced than expected.
According to Kharode et al. [32], rats from 2–15 months are
usually applied in the OVX model, and while use of older
animals is attractive due to steady bone turnover rate, the
use of young adult rats can also provide consistent, repro-
ducible, and interpretable results. Ovariectomy of skeletally
immature rats results in achievement of a lower peak bone
mass (total bone mass present at the end of the skeletal
maturation) which for rats is considered to occur between
47–61 weeks of age [33].PPAR Research 7
Table 6: Mean values ± SD of bone architecture parameters in the femoral metaphysis, determined by means of μCT scanning analyses in
sham controls, ovariectomized controls, and ovariectomized rats fed TTA for four months (Study II).
Femoral metaphysis CTR SHAM (sham-operated
controls, N = 10)
CTR OVX (ovariectomized
controls, N = 10)
TTA OVX (ovariectomized,
given TTA, N = 10)
Cortical volume (Ct.V) (μm3)2 8 .77 ±1.773 27.13 ±1.551a 28.39 ± 2.000
Cortical thickness (Ct.Th) (μm) 735.5 ±22.90 694.4 ±41.84a 693.8 ±28.02aa
Trabecular bone volume (BV) (μm3)6 .554 ±0.8317 5.147 ±0.5373aa 5.300 ±2.20a
Total volume (EV) (μm3)2 1 .85 ±1.640 25.23 ±1.734aaa 25.88 ±2.777aaa
Trabecular thickness (Tb.Th) (μm) 148.3 ± 5.638 146.7 ±6.034 147.5 ± 6.927
Connectivity density (CD) (1/mm3)1 4 .20 ± 5.740 10.91 ±2.118 10.97 ± 3.978
Structure model index (SMI) (0.0–3.0) 0.6682 ±0.2296 1.596 ±0.2397aaa 1.578 ±0.1939aaa
Trabecular bone volume fraction
(BV/TV) 0.2991 ±0.03208 0.2056 ±0.02008aaa 0.2030 ±0.02983aaa
a,aa,aaaP<0.05, P<0.01, P<0.001 when compared to CTR SHAM group.
Table 7: Biomechanical properties of the femoral neck and shaft in mean values ± SD in sham controls, ovariectomized controls, and
ovariectomized rats fed TTA for four months (Study II).
CTR SHAM
(sham-operated controls)
(N = 10)
CTR OVX
(ovariectomized controls)
(N = 10)
TTA OVX
(ovariectomized, given TTA)
(N = 10)
Ultimate bending moment (Nm)
Femoral neck 63.0 ±8.95 2 .1 ±8.9a 49.6 ±13.3a
Femoral shaft 81.7 ±6.37 6 .8 ±7.67 5 .8 ±7.6
Energy absorption (J × 10
−2)
Femoral neck 13.5 ±2.79 .94 ±2.6a 11.9 ± 4.7
Femoral shaft 15.3 ±2.31 3 .3 ±2.81 5 .1 ±3.0
Bending stiﬀness (Nm/◦ × 10
−2)
Femoral neck 370 ±58 317 ±53 290 ±105
Femoral shaft 574 ±61 582 ±58 510 ±92
aP<0.05 when compared to CTR SHAM group.
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Figure 1: The eﬀect of TTA (1nm–100 μM) on RAW 264.7
preosteoclast cell proliferation. Data are in mean ± SD and
presented as relative light units (RLU) in % of control (untreated
cells at same time point), aP<0.05 when compared to control.
There was no diﬀerence in osteocalcin levels in Study
I, while in Study II, circulating osteocalcin was increased
in both the OVX groups. It is diﬃcult to diﬀerentiate if
the elevated level of plasma osteocalcin level in the TTA
group is due to increased bone formation or increased
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Figure 2: The eﬀect of TTA (1.0, 10 and 100μM) on osteo-
protegerin (OPG) release to the cell medium from MC3T3-E1
preosteoblast cells after 12, 24, and 48 h of stimulation. Data are
in mean ± SD and presented as OPG related to the amount of total
protein and as % of control (untreated cells at same time point),
aP<0.05 when compared to control.8 PPAR Research
bone turnover associated with ovariectomy. We have pre-
viously shown that rats that received the PPARα agonist
fenoﬁbrate had increased osteocalcin levels, both in intact
and ovariectomized rats, and that fenoﬁbrate stimulates
MC3T3-E1 osteoblast diﬀerentiation in vitro [7, 8]. We were
not able to demonstrate any signiﬁcant eﬀect of TTA on
osteoblast diﬀerentiation of rat bone marrow cells in our
study; however, a tendency towards increased ALP-positive
colonies was observed. Still et al. demonstrated that the
observed increase in bone mass induced by the PPARα/δ
agonistslinoleicacidandbezaﬁbratewasaresultofincreased
bone formation in mice [16].
The levels of the plasma bone resorption marker CTX
was similar in all groups in both Study I and II. This could
be due to fact that the rats were not fasted. We ﬁnd that TTA
stimulates the release of OPG from preosteoblasts, without
aﬀecting the release of sRANKL, which implies an inhibitory
eﬀect on bone resorption. We also demonstrate that TTA
inhibits proliferation of RAW 264.7 preosteoclasts in a dose-
dependent manner, which indicates that TTA might exert an
inhibitoryeﬀectonosteoclastprecursorrecruitment.Inspite
of the in vitro ﬁndings, we observed no diﬀerence in total
volume between the TTA OVX group and the CTR OVX,
indicating that TTA was not able to prevent the increased
endosteal bone resorption caused by estrogen deﬁciency.
Medullary area in intact rats was similar in both the TTA and
the control groups.
Previously, it has been demonstrated that TTA acts as
a PPARpan agonist in vitro [34]. However, the potency of
TTA-mediated PPAR transactivation and the degree of TTA-
induced activation of the individual PPAR subtypes seem to
beasubjectofcelltypespeciﬁcvariation[34].Theaﬃnityfor
diﬀerentPPARsin bone cellshas so farnot been investigated.
TTA is found to activate all PPAR subtypes in the ranking
order PPARα>PPARδ>PPARγ in rodent cells [35]. The
PPARα agonist fenoﬁbrate increases BMD in intact female
rats and maintains BMD, microarchitecture, and mechanical
strength in ovariectomized rats, in contrast to the negative
eﬀects of the PPARγ agonist pioglitazone [7].
The skeletal eﬀects observed in the present study are less
pronounced than what we found for fenoﬁbrate [7]. This
may be due to a lower potency for PPARα, combined with a
possible coactivation of PPARγ. Due to the negative eﬀects
of PPARγ agonists on bone, it is possible that TTA, as a
PPARpan agonist, might cause a harmful skeletal eﬀect at
very high doses. This was, however, not observed in our
study. The eﬀect of PPARδ activation on bone is so far not
elucidated.
Recently, a new class of free fatty acids receptors has
been identiﬁed [36, 37]. G-protein receptor (GRP), 41 and
GRP43 are activated by short-chain FFAs, whereas GPR40
and GPR120 can be activated by medium- and long-chain
FFAs [36, 37]. Cornish et al. have described the expression of
GRP120 in osteoblasts as well as osteoclasts, while GRP40,
41, and 43 was expressed in osteoclasts only [17]. TTA
may exert PPAR independent eﬀects [35], possibly through
activation of GRP receptors in bone cells.
Recently, in a double-blinded, placebo-controlled study,
we assessed the metabolic eﬀects of systemic TTA in patients
with mild to moderate psoriasis, 1.0g TTA for 28 days
[38]. The most important ﬁndings were that TTA reduced
the plasma lipids (cholesterol, triglycerides, and total fatty
acid) and showed anti-inﬂammatory eﬀects as it lowered the
plasma tumor necrosis factor-α and vascular cell adhesion
molecule-1. No signiﬁcant adverse eﬀects or other com-
plications were reported throughout the study. All safety
parametersremainedwithinthenormallimitsbothformales
and females in the placebo and TTA group [38].
In conclusion, we show that the modiﬁed fatty acid TTA
seems to have some positive skeletal eﬀects, by increasing
femoral BMD in intact female rats and partly preventing
bone loss and impairment of microarchitecture in ovariec-
tomized rats. Since TTA might be used in the treatment
of metabolic syndrome, it is of importance to show that
TTA has no harmful eﬀects on bone like PPARγ agonists as
glitazones.
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